128 related articles for article (PubMed ID: 15307410)
1. Comparison of methods for estimating drug coverage for filariasis elimination, Leogane Commune, Haiti.
Mathieu E; Deming M; Lammie PJ; McLaughlin SI; Beach MJ; Deodat DJ; Addiss DG
Trans R Soc Trop Med Hyg; 2003; 97(5):501-5. PubMed ID: 15307410
[TBL] [Abstract][Full Text] [Related]
2. The Leogane, Haiti demonstration project: decreased microfilaremia and program costs after three years of mass drug administration.
de Rochars MB; Kanjilal S; Direny AN; Radday J; Lafontant JG; Mathieu E; Rheingans RD; Haddix AC; Streit TG; Beach MJ; Addiss DG; Lammie PJ
Am J Trop Med Hyg; 2005 Nov; 73(5):888-94. PubMed ID: 16282299
[TBL] [Abstract][Full Text] [Related]
3. Endpoints for lymphatic filariasis programs.
Grady CA; de Rochars MB; Direny AN; Orelus JN; Wendt J; Radday J; Mathieu E; Roberts JM; Streit TG; Addiss DG; Lammie PJ
Emerg Infect Dis; 2007 Apr; 13(4):608-10. PubMed ID: 17553278
[TBL] [Abstract][Full Text] [Related]
4. Frequency, severity, and costs of adverse reactions following mass treatment for lymphatic filariasis using diethylcarbamazine and albendazole in Leogane, Haiti, 2000.
McLaughlin SI; Radday J; Michel MC; Addiss DG; Beach MJ; Lammie PJ; Lammie J; Rheingans R; Lafontant J
Am J Trop Med Hyg; 2003 May; 68(5):568-73. PubMed ID: 12812348
[TBL] [Abstract][Full Text] [Related]
5. Participation in three consecutive mass drug administrations in Leogane, Haiti.
Mathieu E; Direny AN; de Rochars MB; Streit TG; Addiss DG; Lammie PJ
Trop Med Int Health; 2006 Jun; 11(6):862-8. PubMed ID: 16772008
[TBL] [Abstract][Full Text] [Related]
6. Albendazole for lymphatic filariasis.
Critchley J; Addiss D; Gamble C; Garner P; Gelband H; Ejere H;
Cochrane Database Syst Rev; 2005 Oct; (4):CD003753. PubMed ID: 16235339
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of the use of vector control and mass drug administration, separately or in combination, against lymphatic filariasis.
Krishnamoorthy K; Rajendran R; Sunish IP; Reuben R
Ann Trop Med Parasitol; 2002 Dec; 96 Suppl 2():S77-90. PubMed ID: 12625921
[TBL] [Abstract][Full Text] [Related]
8. Albendazole for lymphatic filariasis.
Addiss D; Critchley J; Ejere H; Garner P; Gelband H; Gamble C;
Cochrane Database Syst Rev; 2004; (1):CD003753. PubMed ID: 14974034
[TBL] [Abstract][Full Text] [Related]
9. Model-based analysis of trial data: microfilaria and worm-productivity loss after diethylcarbamazine-albendazole or ivermectin-albendazole combination therapy against Wuchereria bancrofti.
de Kraker ME; Stolk WA; van Oortmarssen GJ; Habbema JD
Trop Med Int Health; 2006 May; 11(5):718-28. PubMed ID: 16640625
[TBL] [Abstract][Full Text] [Related]
10. Community-wide reduction in prevalence and intensity of intestinal helminths as a collateral benefit of lymphatic filariasis elimination programs.
De Rochars MB; Direny AN; Roberts JM; Addiss DG; Radday J; Beach MJ; Streit TG; Dardith D; Lafontant JG; Lammie PJ
Am J Trop Med Hyg; 2004 Oct; 71(4):466-70. PubMed ID: 15516644
[TBL] [Abstract][Full Text] [Related]
11. Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.
Bockarie MJ; Alexander ND; Hyun P; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
Lancet; 1998 Jan; 351(9097):162-8. PubMed ID: 9449870
[TBL] [Abstract][Full Text] [Related]
12. Economic performance and cost-effectiveness of using a DEC-salt social enterprise for eliminating the major neglected tropical disease, lymphatic filariasis.
Sharma S; Smith ME; Reimer J; O'Brien DB; Brissau JM; Donahue MC; Carter CE; Michael E
PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007094. PubMed ID: 31260444
[TBL] [Abstract][Full Text] [Related]
13. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
Jambulingam P; Subramanian S; de Vlas SJ; Vinubala C; Stolk WA
Parasit Vectors; 2016 Sep; 9(1):501. PubMed ID: 27624157
[TBL] [Abstract][Full Text] [Related]
14. Elimination of transmission of lymphatic filariasis in Egypt.
Molyneux DH
Lancet; 2006 Mar; 367(9515):966-8. PubMed ID: 16564345
[No Abstract] [Full Text] [Related]
15. Reducing the Antigen Prevalence Target Threshold for Stopping and Restarting Mass Drug Administration for Lymphatic Filariasis Elimination: A Model-Based Cost-effectiveness Simulation in Tanzania, India and Haiti.
Antony Oliver MC; Graham M; Gass KM; Medley GF; Clark J; Davis EL; Reimer LJ; King JD; Pouwels KB; Hollingsworth TD
Clin Infect Dis; 2024 Apr; 78(Supplement_2):S160-S168. PubMed ID: 38662697
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study.
Irvine MA; Stolk WA; Smith ME; Subramanian S; Singh BK; Weil GJ; Michael E; Hollingsworth TD
Lancet Infect Dis; 2017 Apr; 17(4):451-458. PubMed ID: 28012943
[TBL] [Abstract][Full Text] [Related]
17. Mass treatment to eliminate filariasis in Papua New Guinea.
Bockarie MJ; Tisch DJ; Kastens W; Alexander ND; Dimber Z; Bockarie F; Ibam E; Alpers MP; Kazura JW
N Engl J Med; 2002 Dec; 347(23):1841-8. PubMed ID: 12466508
[TBL] [Abstract][Full Text] [Related]
18. Impact of 10 years of diethylcarbamazine and ivermectin mass administration on infection and transmission of lymphatic filariasis.
Ramaiah KD; Das PK; Vanamail P; Pani SP
Trans R Soc Trop Med Hyg; 2007 Jun; 101(6):555-63. PubMed ID: 17374389
[TBL] [Abstract][Full Text] [Related]
19. Prospects for elimination of bancroftian filariasis by mass drug treatment in Pondicherry, India: a simulation study.
Stolk WA; Swaminathan S; van Oortmarssen GJ; Das PK; Habbema JD
J Infect Dis; 2003 Nov; 188(9):1371-81. PubMed ID: 14593597
[TBL] [Abstract][Full Text] [Related]
20. Strategies and tools for the control/elimination of lymphatic filariasis.
Ottesen EA; Duke BO; Karam M; Behbehani K
Bull World Health Organ; 1997; 75(6):491-503. PubMed ID: 9509621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
